1	Clinical	Clinical	B-NP	JJ	O	2	NMOD	0
2	significance	significance	I-NP	NN	O	0	ROOT	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	plasma	plasma	B-NP	NN	B-protein	5	NMOD	0
5	endostatin	endostatin	I-NP	NN	I-protein	3	PMOD	0
6	in	in	B-PP	IN	O	2	NMOD	0
7	acute	acute	B-NP	JJ	O	10	NMOD	0
8	myeloid	myeloid	I-NP	JJ	O	10	NMOD	0
9	leukemia/myelodysplastic	leukemia/myelodysplastic	I-NP	JJ	O	10	NMOD	0
10	syndrome	syndrome	I-NP	NN	O	6	PMOD	0
11	.	.	O	.	O	2	P	0

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Endostatin	Endostatin	B-NP	NN	B-protein	7	NMOD	0
4	,	,	O	,	O	7	P	0
5	a	a	B-NP	DT	O	7	NMOD	0
6	C-terminal	C-terminal	I-NP	JJ	B-protein	7	NMOD	0
7	fragment	fragment	I-NP	NN	I-protein	1	NMOD	0
8	of	of	B-PP	IN	O	7	NMOD	0
9	collagen	collagen	B-NP	NN	B-protein	10	NMOD	0
10	XVIII	XVIII	I-NP	NN	I-protein	8	PMOD	0
11	,	,	O	,	O	7	P	0
12	is	be	B-VP	VBZ	O	1	NMOD	0
13	an	an	B-NP	DT	O	16	NMOD	0
14	endogenous	endogenous	I-NP	JJ	O	16	NMOD	0
15	angiogenesis	angiogenesis	I-NP	NN	O	16	NMOD	3	angiogenesis
16	inhibitor	inhibitor	I-NP	NN	O	12	PRD	0
17	.	.	O	.	O	12	P	0

1	While	While	B-SBAR	IN	O	19	VMOD	0
2	endostatin	endostatin	B-NP	NN	B-protein	3	SUB	0
3	is	be	B-VP	VBZ	O	1	SBAR	0
4	being	be	I-VP	VBG	O	3	VC	0
5	investigated	investigate	I-VP	VBN	O	4	VC	0
6	for	for	B-PP	IN	O	5	VMOD	0
7	its	its	B-NP	PRP$	O	8	NMOD	0
8	usefulness	usefulness	I-NP	NN	O	6	PMOD	0
9	in	in	B-PP	IN	O	5	VMOD	0
10	treating	treat	B-VP	VBG	O	9	PMOD	19	treating
11	solid	solid	B-NP	JJ	O	12	NMOD	0
12	tumors	tumor	I-NP	NNS	O	10	OBJ	0
13	,	,	O	,	O	19	P	0
14	its	its	B-NP	PRP$	O	15	NMOD	0
15	significance	significance	I-NP	NN	O	19	SUB	0
16	in	in	B-PP	IN	O	15	NMOD	0
17	hematologic	hematologic	B-NP	JJ	O	18	NMOD	0
18	malignancies	malignancy	I-NP	NNS	O	16	PMOD	0
19	is	be	B-VP	VBZ	O	0	ROOT	0
20	unknown	unknown	B-ADJP	JJ	O	19	PRD	0
21	.	.	O	.	O	19	P	0

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	The	The	B-NP	DT	O	4	NMOD	0
4	authors	author	I-NP	NNS	O	5	SUB	0
5	evaluated	evaluate	B-VP	VBD	O	1	NMOD	0
6	plasma	plasma	B-NP	NN	O	7	NMOD	0
7	endostatin	endostatin	I-NP	NN	O	11	NMOD	0
8	(	(	O	(	O	10	DEP	0
9	PE	PE	B-NP	NN	O	10	DEP	0
10	)	)	O	)	O	7	NMOD	0
11	levels	level	B-NP	NNS	O	5	OBJ	0
12	using	use	B-VP	VBG	O	5	VMOD	0
13	an	an	B-NP	DT	O	16	NMOD	0
14	enzyme	enzyme	I-NP	NN	O	16	NMOD	0
15	linked	link	I-NP	VBN	O	16	NMOD	0
16	immunoassay	immunoassay	I-NP	NN	O	12	OBJ	0
17	in	in	B-PP	IN	O	16	NMOD	0
18	71	71	B-NP	CD	O	19	NMOD	0
19	patients	patient	I-NP	NNS	O	17	PMOD	0
20	with	with	B-PP	IN	O	19	NMOD	0
21	acute	acute	B-NP	JJ	O	23	NMOD	0
22	myeloid	myeloid	I-NP	JJ	O	23	NMOD	0
23	leukemia	leukemia	I-NP	NN	O	29	NMOD	0
24	(	(	O	(	O	26	DEP	0
25	AML	AML	B-NP	NN	O	26	DEP	0
26	)	)	O	)	O	23	NMOD	0
27	and	and	O	CC	O	29	NMOD	0
28	43	43	B-NP	CD	O	29	NMOD	0
29	patients	patient	I-NP	NNS	O	20	PMOD	0
30	with	with	B-PP	IN	O	29	NMOD	0
31	myelodysplastic	myelodysplastic	B-NP	JJ	O	32	NMOD	0
32	syndrome	syndrome	I-NP	NN	O	30	PMOD	0
33	(	(	O	(	O	35	DEP	0
34	MDS	MDS	B-NP	NN	O	35	DEP	0
35	)	)	O	)	O	32	NMOD	0
36	,	,	O	,	O	5	P	0
37	and	and	O	CC	O	5	VMOD	0
38	correlated	correlate	B-VP	VBD	O	5	VMOD	0
39	PE	PE	B-NP	NN	O	38	OBJ	0
40	with	with	B-PP	IN	O	38	VMOD	0
41	various	various	B-NP	JJ	O	43	NMOD	0
42	clinical	clinical	I-NP	JJ	O	43	NMOD	0
43	parameters	parameter	I-NP	NNS	O	40	PMOD	0
44	.	.	O	.	O	1	P	0

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	There	There	B-NP	EX	O	4	SUB	0
4	was	be	B-VP	VBD	O	1	NMOD	0
5	no	no	B-NP	DT	O	7	NMOD	0
6	significant	significant	I-NP	JJ	O	7	NMOD	0
7	difference	difference	I-NP	NN	O	4	PRD	0
8	in	in	B-PP	IN	O	7	NMOD	0
9	the	the	B-NP	DT	O	12	NMOD	0
10	median	median	I-NP	JJ	O	12	NMOD	0
11	PE	PE	I-NP	NN	O	12	NMOD	0
12	level	level	I-NP	NN	O	8	PMOD	0
13	between	between	B-PP	IN	O	7	NMOD	0
14	AML/MDS	AML/MDS	B-NP	NN	O	15	NMOD	0
15	patients	patient	I-NP	NNS	O	19	NMOD	0
16	and	and	O	CC	O	19	NMOD	0
17	the	the	B-NP	DT	O	19	NMOD	0
18	normal	normal	I-NP	JJ	O	19	NMOD	0
19	controls	control	I-NP	NNS	O	13	PMOD	0
20	.	.	O	.	O	1	P	0

1	Nevertheless	Nevertheless	B-ADVP	RB	O	11	VMOD	0
2	,	,	O	,	O	11	P	0
3	patients	patient	B-NP	NNS	O	11	SUB	0
4	who	who	B-NP	WP	O	3	NMOD	0
5	achieved	achieve	B-VP	VBD	O	4	SBAR	0
6	complete	complete	B-NP	JJ	O	7	NMOD	0
7	remission	remission	I-NP	NN	O	5	OBJ	0
8	(	(	O	(	O	10	DEP	0
9	CR	CR	B-NP	NN	O	10	DEP	0
10	)	)	O	)	O	3	NMOD	0
11	had	have	B-VP	VBD	O	0	ROOT	0
12	a	a	B-NP	DT	O	17	NMOD	0
13	significantly	significantly	I-NP	RB	O	14	AMOD	0
14	lower	low	I-NP	JJR	O	15	AMOD	0
15	median	median	I-NP	JJ	O	17	NMOD	0
16	PE	PE	I-NP	NN	O	17	NMOD	0
17	level	level	I-NP	NN	O	11	OBJ	0
18	compared	compare	B-VP	VBN	O	11	VMOD	0
19	to	to	B-PP	TO	O	18	PMOD	0
20	those	those	B-NP	DT	O	19	PMOD	0
21	who	who	B-NP	WP	O	20	NMOD	0
22	did	do	B-VP	VBD	O	21	SBAR	0
23	not	not	O	RB	O	22	VMOD	0
24	.	.	O	.	O	11	P	0

1	In	In	B-PP	IN	O	6	VMOD	0
2	multivariate	multivariate	B-NP	JJ	O	3	NMOD	0
3	analysis	analysis	I-NP	NN	O	1	PMOD	0
4	,	,	O	,	O	6	P	0
5	PE	PE	B-NP	NN	O	6	SUB	0
6	was	be	B-VP	VBD	O	0	ROOT	0
7	found	find	I-VP	VBN	O	6	VC	0
8	to	to	I-VP	TO	O	9	VMOD	0
9	be	be	I-VP	VB	O	7	VMOD	0
10	a	a	B-NP	DT	O	11	NMOD	0
11	significant	significant	I-NP	JJ	O	44	NMOD	0
12	(	(	O	(	O	16	DEP	0
13	P	P	B-NP	NN	O	16	DEP	0
14	=	=	B-VP	SYM	O	13	NMOD	0
15	0.03	0.03	B-NP	CD	O	14	AMOD	0
16	)	)	O	)	O	11	NMOD	0
17	predictor	predictor	B-NP	NN	O	11	NMOD	0
18	of	of	B-PP	IN	O	11	NMOD	0
19	overall	overall	B-NP	JJ	O	20	NMOD	0
20	survival	survival	I-NP	NN	O	18	PMOD	0
21	(	(	O	(	O	23	DEP	0
22	OS	OS	B-NP	NN	O	23	DEP	0
23	)	)	O	)	O	20	NMOD	0
24	with	with	B-PP	IN	O	20	NMOD	0
25	adjustment	adjustment	B-NP	NN	O	24	PMOD	0
26	of	of	B-PP	IN	O	25	NMOD	0
27	the	the	B-NP	DT	O	30	NMOD	0
28	other	other	I-NP	JJ	O	30	NMOD	0
29	baseline	baseline	I-NP	NN	O	30	NMOD	0
30	covariates	covariate	I-NP	NNS	O	26	PMOD	0
31	,	,	O	,	O	30	P	0
32	including	include	B-PP	VBG	O	30	NMOD	0
33	patient	patient	B-NP	NN	O	34	NMOD	0
34	age	age	I-NP	NN	O	36	NMOD	0
35	,	,	O	,	O	36	P	0
36	history	history	B-NP	NN	O	32	PMOD	0
37	of	of	B-PP	IN	O	36	NMOD	0
38	antecedent	antecedent	B-NP	JJ	O	40	NMOD	0
39	hematologic	hematologic	I-NP	JJ	O	40	NMOD	0
40	disorders	disorder	I-NP	NNS	O	37	PMOD	0
41	,	,	O	,	O	44	P	0
42	and	and	O	CC	O	44	NMOD	0
43	the	the	B-NP	DT	O	44	NMOD	0
44	use	use	I-NP	NN	O	9	PRD	0
45	of	of	B-PP	IN	O	44	NMOD	0
46	protective	protective	B-NP	JJ	O	47	NMOD	0
47	environments	environment	I-NP	NNS	O	45	PMOD	0
48	.	.	O	.	O	6	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	prognostic	prognostic	I-NP	JJ	O	3	NMOD	0
3	value	value	I-NP	NN	O	6	SUB	0
4	of	of	B-PP	IN	O	3	NMOD	0
5	PE	PE	B-NP	NN	O	4	PMOD	0
6	was	be	B-VP	VBD	O	0	ROOT	0
7	also	also	I-VP	RB	O	6	VMOD	0
8	evaluated	evaluate	I-VP	VBN	O	6	VC	0
9	by	by	B-PP	IN	O	8	VMOD	0
10	dividing	divide	B-VP	VBG	O	9	PMOD	0
11	MDS/AML	MDS/AML	B-NP	NN	O	12	NMOD	0
12	patients	patient	I-NP	NNS	O	10	OBJ	0
13	into	into	B-PP	IN	O	10	VMOD	0
14	high	high	B-NP	JJ	O	18	NMOD	0
15	and	and	I-NP	CC	O	18	NMOD	0
16	low	low	I-NP	JJ	O	18	NMOD	0
17	PE	PE	I-NP	NN	O	18	NMOD	0
18	groups	group	I-NP	NNS	O	13	PMOD	0
19	using	use	B-VP	VBG	O	10	VMOD	0
20	the	the	B-NP	DT	O	23	NMOD	0
21	median	median	I-NP	JJ	O	23	NMOD	0
22	PE	PE	I-NP	NN	O	23	NMOD	0
23	level	level	I-NP	NN	O	19	OBJ	0
24	of	of	B-PP	IN	O	23	NMOD	0
25	normal	normal	B-NP	JJ	O	26	NMOD	0
26	controls	control	I-NP	NNS	O	24	PMOD	0
27	as	as	B-PP	IN	O	19	VMOD	0
28	the	the	B-NP	DT	O	29	NMOD	0
29	cut-off	cut-off	I-NP	NN	B-protein	27	PMOD	0
30	.	.	O	.	O	6	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	authors	author	I-NP	NNS	O	3	SUB	0
3	found	find	B-VP	VBD	O	0	ROOT	0
4	that	that	B-SBAR	IN	O	3	VMOD	0
5	patients	patient	B-NP	NNS	O	11	SUB	0
6	in	in	B-PP	IN	O	5	NMOD	0
7	the	the	B-NP	DT	O	10	NMOD	0
8	high	high	I-NP	JJ	O	10	NMOD	0
9	PE	PE	I-NP	NN	O	10	NMOD	0
10	group	group	I-NP	NN	O	6	PMOD	0
11	survived	survive	B-VP	VBD	O	4	SBAR	5	survived
12	for	for	B-PP	IN	O	11	VMOD	0
13	a	a	B-NP	DT	O	16	NMOD	0
14	significantly	significantly	I-NP	RB	O	15	AMOD	0
15	shorter	short	I-NP	JJR	O	16	NMOD	0
16	time	time	I-NP	NN	O	12	PMOD	0
17	than	than	B-PP	IN	O	11	VMOD	0
18	those	those	B-NP	DT	O	19	NMOD	0
19	patients	patient	I-NP	NNS	O	17	PMOD	0
20	in	in	B-PP	IN	O	19	NMOD	0
21	the	the	B-NP	DT	O	24	NMOD	0
22	low	low	I-NP	JJ	O	24	NMOD	0
23	PE	PE	I-NP	NN	O	24	NMOD	0
24	group	group	I-NP	NN	O	20	PMOD	0
25	.	.	O	.	O	3	P	0

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	PE	PE	B-NP	NN	O	4	SUB	0
4	is	be	B-VP	VBZ	O	1	NMOD	0
5	a	a	B-NP	DT	O	8	NMOD	0
6	useful	useful	I-NP	JJ	O	8	NMOD	0
7	prognostic	prognostic	I-NP	JJ	O	8	NMOD	0
8	predictor	predictor	I-NP	NN	O	4	PRD	0
9	of	of	B-PP	IN	O	8	NMOD	0
10	CR	CR	B-NP	NN	O	12	NMOD	0
11	and	and	I-NP	CC	O	12	NMOD	0
12	OS	OS	I-NP	NN	O	9	PMOD	0
13	for	for	B-PP	IN	O	12	NMOD	0
14	AML/MDS	AML/MDS	B-NP	NN	O	15	NMOD	0
15	patients	patient	I-NP	NNS	O	13	PMOD	0
16	.	.	O	.	O	1	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	mechanism	mechanism	I-NP	NN	O	13	SUB	0
3	underlying	underlie	B-VP	VBG	O	2	NMOD	0
4	the	the	B-NP	DT	O	5	NMOD	0
5	association	association	I-NP	NN	O	3	OBJ	0
6	between	between	B-PP	IN	O	5	NMOD	0
7	high	high	B-NP	JJ	O	8	NMOD	0
8	PE	PE	I-NP	NN	O	12	NMOD	0
9	and	and	O	CC	O	12	NMOD	0
10	poor	poor	B-NP	JJ	O	11	AMOD	0
11	clinical	clinical	I-NP	JJ	O	12	NMOD	0
12	outcome	outcome	I-NP	NN	O	6	PMOD	0
13	is	be	B-VP	VBZ	O	0	ROOT	0
14	unclear	unclear	B-ADJP	JJ	O	13	PRD	0
15	,	,	O	,	O	13	P	0
16	although	although	B-SBAR	IN	O	13	VMOD	0
17	it	it	B-NP	PRP	O	18	SUB	0
18	may	may	B-VP	MD	O	16	SBAR	0
19	be	be	I-VP	VB	O	18	VC	0
20	related	related	B-ADJP	JJ	O	19	PRD	0
21	to	to	B-PP	TO	O	20	AMOD	0
22	the	the	B-NP	DT	O	25	NMOD	0
23	possible	possible	I-NP	JJ	O	25	NMOD	0
24	PE	PE	I-NP	NN	O	25	NMOD	0
25	reflection	reflection	I-NP	NN	O	21	PMOD	0
26	of	of	B-PP	IN	O	25	NMOD	0
27	tumor	tumor	B-NP	NN	O	28	NMOD	0
28	burden	burden	I-NP	NN	O	26	PMOD	0
29	.	.	O	.	O	13	P	0

